PURPOSE: To assess efficacy, stability and safety of posterior chamber phakic intraocular lens implantation with STAAR Visian ICL for correction of high @entity2516 , with a mean follow-up of 5 years (3.5-10 years). @entity1 AND METHODS: Ninety eyes of 53 highly ametropic @entity1 (45 @entity1714 , ten @entity3467 and 35 with mixed @entity940 ) were included in a retrospective single-surgeon study, using primarily the V4 ICL model (87 eyes). We studied pre- and postoperative refractive efficacy, endothelial cell density, crystalline lens opacification and intraocular clearances within the various compartments of the eye. RESULTS: Mean uncorrected visual acuity was 0.77 at the 12th postoperative month; 17 of 90 eyes required adjunctive photoablation for residual @entity940 . Forty-eight percent of eyes gained at least one line of best corrected visual acuity. After implantation, the decrease in endothelial cell density remained stable at 0.69%/year, and 91% of eyes showed no opacification of the crystalline lens. Mean endothelium-ICL and ICL-crystalline lens distances were 2.41 mm and 0.52 mm respectively. Overall @entity1 satisfaction achieved was 96% at 36 months postoperatively. DISCUSSION AND CONCLUSION: These results demonstrate efficacy, stability and safety of the ICL V4 phakic IOL for the correction of high @entity2516 . Long-term follow-up did not show a significant increase in @entity231 formation in implanted eyes.

[Long-term results of posterior chamber phakic intraocular lens implantation for correction of high XXXX ].

@entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'PATIENTS'] @entity940 :: ('MESH:D001251', 'Disease') :: ['astigmatism'] @entity2516 :: ('MESH:D012030', 'Disease') :: ['ametropia'] @entity231 :: ('MESH:D002386', 'Disease') :: ['cataract'] @entity3467 :: ('MESH:D006956', 'Disease') :: ['hyperopia'] @entity1714 :: ('MESH:D009216', 'Disease') :: ['myopia']
@entity2516 :: (MESH:D012030,Disease) :: ['ametropia']
